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Abstract
Hypertension is a major risk factor for cardiovascular 
disease, resulting in increased incidence of cerebro-
vascular events, ischaemic heart disease, heart failure, 
and renal impairment. Thus, it is one of the most im-
portant preventable causes of premature morbidity and 
mortality. Despite current knowledge on the manage-
ment of hypertension and the availability of several ef-
fective antihypertensive medications, uncontrolled hy-
pertension remains a common and challenging clinical 
problem. Resistant hypertension is a complex condition 
with multiple contributing factors and overlapping co-
morbidities. Although there is limited hard evidence 
regarding resistant hypertension, our understanding 
of this condition has improved recently. This article 
will present an overview of resistant hypertension and 
highlight recent publications about this topic.
© 2012 Baishideng. All rights reserved.
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INTRODUCTION
Resistant hypertension is defined as high blood pres-
sure (BP) in spite of  appropriate lifestyle interventions 
and administration of  three different antihypertensive 
drugs at optimal dose amounts, which should include a 
diuretic agent[1,2]. The goal systolic BP is usually defined 
as < 140 mmHg and < 90 mmHg for diastolic BP; how-
ever, current views on cardiovascular risk suggest lower 
targets for high-risk patients (e.g., those with diabetes 
mellitus, renal dysfunction). By this definition, subjects 
who achieve adequate BP control with optimal doses of  
4 or more antihypertensive medications are considered 
to have resistant hypertension. This group of  patients 
controlled with ≥ 4 drugs accounts for 30% of  the re-
sistant hypertension cases[3], and should be considered 
as a separate category in future studies (as they seem to 
represent a more benign phenotype), to better charac-
terize the most severe forms of  truly resistant hyperten-
sion. Although arbitrary, the above definition focuses 
on a subset of  hypertensive patients with a higher cardio-
vascular risk and potentially reversible causes of  hyper-
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tension that should be thoroughly pursued. Prognosis 
among patients with resistant hypertension compared 
with those who are non-resistant, though expectedly 
worse, is not well established in the literature[4,5]. Re-
sistant hypertension pathophysiology needs a greater 
understanding, as does its incidence and prognosis. 
Whether the worse cardiovascular outcome is related 
to a resistant-to-treatment phenotype or linked to BP 
control also needs to be better understood. Knowing 
the patterns of  medication class use, the importance 
of  medication adherence, and the efficacy of  certain 
therapy interventions (change in medication class, in-
crease in drug dose, novel antihypertensive treatments) 
in a population with resistant hypertension would help 
to guide future interventions and improve management 
of  these challenging patients.
PREVALENCE
The prevalence of  resistant hypertension, though not un-
common, is not well established and has been defined as 
a priority area in future studies[2]. There is no specifically 
designed research concerning resistant hypertension, 
and our knowledge mainly derives from cross-sectional 
analyses and some recent clinical trials. However, failure 
to apply a uniform definition of  resistant hypertension, 
very selective populations, restricted treatment regimens, 
and the inability to exclude pseudoresistant hypertension 
has limited the interpretation of  results. The 2003 to 
2008 National Health and Nutrition Examination Survey 
included > 15 000 unselected adults in the United States, 
and found resistant hypertension criteria to be met in 
8.9% of  all individuals with hypertension, and in 12.8% 
of  the hypertensive drug-treated population[5]. Another 
large survey in Spanish hypertensive patients found simi-
lar results, with 12.2% incidence of  resistant hyperten-
sion in treated patients[6]. The work by Daugherty et al[5] 
has found that 16% of  the patients were taking ≥ 3 
medications, once they had excluded poor adherence to 
treatment regimens. Furthermore, this study has shown 
that 1 in 50 cases in whom antihypertensive treatment 
is started will develop resistant hypertension within 1.5 
years[4]. Nonetheless, in a progressively older population, 
with an increasing incidence of  comorbidities related to 
resistant hypertension such as diabetes, obesity and renal 
impairment, the prevalence of  resistant-to-treatment hy-
pertension is much more likely to increase.  
PSEUDORESISTANCE
Inaccurate measurement of BP
A poor BP measurement technique can often be mis-
leading. The most common errors are an inappropriate 
cuff  size, incorrect patient and arm positions, and inade-
quate premeasurement at rest. Moreover, marked arterial 
stiffness which does not compress with pressure should 
be seen as a potential cause of  pseudohypertension, 
especially in the elderly or in those with other treatment 
symptoms.
Poor adherence to therapeutic plans
Non-adherence to lifestyle interventions and/or anti-
hypertensive therapy is a major cause of  uncontrolled 
hypertension. About half  of  the patients who were 
prescribed an antihypertensive drug had stopped taking 
it within one year[7]. Factors that influence adherence 
include patient demographics, side effects of  medica-
tions, convenience of  drug dosing, cost and number of  
medications, as well as patients’ knowledge, beliefs and 
attitudes about hypertension. A study on resistant hyper-
tension highlighted the importance of  patients’ compli-
ance by reporting a BP reduction to normotensive values 
in about 30% of  the participants, attributable merely to 
patient self-perception of  being monitored and with-
out any changes in medication regimen[8]. Nonetheless, 
physician failure to comply with guidelines and actively 
pursue adequate BP in their patients is, also, a significant 
contributor to the lack of  BP control. The latter may be 
illustrated in a recent clinical study which has found that 
resistant hypertension patients were taking less than 50% 
of  the recommended maximal daily doses of  their anti-
hypertensive medications at follow-up[9]. Moreover, pa-
tients already on 3 or more antihypertensive medications 
are at an increased risk for poor treatment adherence 
and clinical inertia (because of  the potential adverse ef-
fects of  multiple drug combinations or physician scepti-
cism about the benefit of  intensifying therapy).
White-coat effect 
Most patients have higher BP levels when measured 
by the physician than when assessed out of  the office. 
This “white-coat” effect is often more pronounced in 
patients with severe hypertension. Moreover, 20%-30% 
of  patients with apparent resistant hypertension referred 
for ambulatory BP monitoring in fact have normal BP 
readings[10]. It is of  note that patients with white-coat 
hypertension have less severe target organ damage and 
cardiovascular risk compared to those with persistent 
elevated BP readings in ambulatory monitoring.
RESISTANT HYPERTENSION
Resistant hypertension should not be confused with un-
controlled hypertension, which includes pseudoresistance, 
inadequate therapeutic regimen, as well as true resistant-
to-treatment hypertension. Thus, resistant hypertension 
is a diagnosis of  exclusion that should be carefully estab-
lished using a stepwise patient evaluation, according to the 
American Heart Association state of  the art manuscript 
on resistant hypertension[2].
In the presence of  uncontrolled hypertension, the 
patient’s evaluation should begin with a correct BP mea-
surement to avoid false high readings, and then confirmed 
by out-of-office BP monitoring to exclude white-coat 
hypertension. Patient compliance assessment is of  ut-
most importance. The next step, after pseudoresistance 
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exclusion, is the identification and possibly reversing of  
contributing lifestyle factors. Obesity is a common feature 
in resistant hypertension patients and is related to poor 
antihypertensive treatment response. It has been reported 
that each 10% increase in weight is associated with a 
6.5 mmHg increase in systolic BP[11]. Dietary salt intake 
can blunt the effects of  the majority of  antihypertensive 
drugs, especially in salt-sensitive patients such as the elder-
ly and black race patients, and in renal impairment. Several 
pharmacological agents can significantly interfere with 
BP and/or antihypertensive effect of  medications; hence 
interfering substances should be promptly discontinued or 
minimized. The recognition of  other common contribut-
ing factors such as non-steroidal anti-inflammatory drug 
use, oral contraceptive hormones or progressive renal 
impairment is needed in order to achieve BP control in 
resistant-to-treatment patients.
Resistant hypertension is complex in nature and al-
most always multifactorial in aetiology. Although uncom-
mon, the potential reversible causes of  hypertension 
should always be carefully ruled out by medical history, 
physical examination, biochemical evaluation, and/or 
non-invasive imaging (Figure 1). Sleep apnoea is among 
the commonest secondary causes of  hypertension. Its 
association with hypertension is due to the sustained 
increase in sympathetic nervous system activity, and its 
prevalence is approximately 85% of  the true resistant-to-
treatment patients[12]. However, continuous positive air-
way pressure has only shown a modest antihypertensive 
benefit[13,14]. Primary aldosteronism seems to be a much 
more common secondary cause of  hypertension than 
previously recognized, with a reported prevalence of  
approximately 20% in resistant hypertension[15]. Recogni-
tion that most patients do not have low serum potassium 
levels, and a more effective screening using aldosterone 
and renin levels, has led to an improved detection of  this 
condition. Renal parenchymal disease and renal artery 
stenosis are other common causes of  secondary hyper-
tension that should be assessed in both analytical and 
imaging modalities. Less common causes including aortic 
coarctation, Cushing syndrome, and pheochromocytoma 
are rarely seen (< 1%)[4]. 
The management of  resistant hypertension is ardu-
ous and involves extensive testing, which should include 
the following: biochemical evaluation, including serum 
sodium, potassium, glucose, and creatinine (creatinine 
clearance); plasma aldosterone and renin; urinalysis; and 
24-h urine collection to estimate dietary sodium, potas-
sium, and aldosterone excretion. Testing for urinary or 
plasma metanephrines/catecholamines is indicated only 
when pheochromocytoma is suspected. Non-invasive 
imaging is mandatory when there is a suspicion of  renal 
artery stenosis, adrenal adenoma/tumour, parenchymal 
renal disease or aortic coarctation.
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Exclude causes of pseudoresistance
• Inaccurate measurement of blood pressure
• Poor adherence to therapeutic plans
• White coat hypertension
Identify and manage contributing lifestyle factors and interfering substances
Screen for potential reversible causes of hypertension
• Obstructive sleep apnoea (snoring, witnessed apnoea, excessive daytime sleepiness)
• Primary aldosteronism (elevated aldosterone/renin ratio)
• Chronic kidney disease (creatinine clearance < 30 mL/min, abnormal urinalysis)
• Renal artery stenosis (abdominal bruit, young female, known atherosclerotic disease, worsening renal function)
• Pheochromocytoma (episodic hypertension, palpitations, orthostatic hypotension, diaphoresis)
• Cushing’s syndrome (moon faces, central obesity abdominal striae, inter-scapular fat deposition)
• Aortic coarctation (differential in brachial or femoral pulses, systolic bruit)
Pharmacological treatment
•	 Use	simplified	regimens	and	long-acting	combination	agents	
• Prefer agent combination with different mechanism of action, at maximal tolerated doses
                 Consider triple drug therapy using ACE inhibitor/ARB + CCB + chlorthalidone
• Use loop diuretic when creatinine clearance < 30 mL/min; at least twice daily dosing
• Use at least one of the antihypertensive drugs at bedtime
• Add aldosterone antagonist (e.g., spironolactone 25-50 mg/d)
• Add other antihypertensive drug class depending on clinical setting
Device-based therapy
•	 Consider	renal	denervation	therapy	in	cases	of	persistently	uncontrolled	hypertension	(carotid	baroreflex	activation	therapy	is	
                under further investigation)
Common
Uncommon
Figure  1  Diagnosis and management algorithm (adapted from Calhoun et al[2]). ACE: Angiotensin-converting enzyme; ARB: Angiotensin receptor blocker; CCB: 
Calcium channel blocker.
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GENETIC CONSIDERATIONS
High BP is a heritable trait influenced by several biologi-
cal pathways and responsive to environmental stimuli. 
The determination of  the genetic variants involved in 
hypertension would provide new insight into BP regula-
tion, and there are several lines of  evidence which point 
towards an important genetic contribution. Further-
more, it is reasonable to expect an even greater genetic 
role in severe phenotypes, as true resistant hypertension. 
To date, few variants associated with interindividual BP 
variation have been consistently identified[16,17], and our 
understanding of  the genetic determinants of  hyper-
tension is in its early phase. Nonetheless, efforts in the 
dissection of  BP genetics would create new targets for 
therapeutic approaches, and future use of  individually 
tailored treatment will improve drug efficacy and reduce 
its toxicity.
TREATMENT RECOMMENDATIONS
If  a specific secondary cause of  hypertension is suspect-
ed or if  the BP is persistently high despite six months 
of  more intensive treatment, patient referral to a hy-
pertension specialist is advised[2]. Recommendations on 
the treatment of  secondary causes of  hypertension are 
beyond the scope of  this review.
Nonpharmacological therapy
This includes reversal of  lifestyle factors contributing to 
treatment resistance, and discontinuation or minimisa-
tion of  interfering substances. There is usually a beneficial 
result with lower salt diet (< 100 mEq of  sodium/24 h), 
ingestion of  low fat and high fibre diet, weight loss in 
obese or overweight patients, moderation of  alcohol 
intake to no more than two drinks per day for most men 
and one drink for women or lighter-weight persons, ad-
vising smoking cessation, and regular physical activity. 
Do not offer calcium, magnesium or potassium supple-
ments as a method for reducing BP[17]. 
Pharmacological therapy
Drug treatment of  resistant hypertension involves, by 
definition, combinations of  three or more drugs. 
Diuretic therapy: Inappropriate volume expansion con-
tributes to resistant hypertension, even among patients al-
ready on thiazide diuretics. In order to increase efficiency 
it may be necessary to add a diuretic, increase the usual 
dose or change to different diuretic class. In those with-
out significant renal impairment, the long acting thiazide 
diuretic chlorthalidone is preferred over hydrochlorothia-
zide for the treatment of  resistant hypertension[18]. It has 
a more potent antihypertensive effect, longer half-life and 
has been shown to achieve better BP control, in com-
parison with hydrochlorothiazide. Among patients with 
an estimated glomerular filtration < 30 mL/min per m2, 
thiazide diuretics become less effective and loop diuretics 
should be used instead, such as furosemide, which needs 
at least twice daily dosing due to its short half-life. In the 
presence of  refractory volume retention, medical inter-
vention should focus on reducing dietary sodium intake 
and increasing the diuretic treatment intensity.  
Aldosterone antagonists: The prevalence of  primary al-
dosteronism in resistant hypertension patients seems to be 
much more common than previously acknowledged, and 
recent studies using aldosterone antagonists, such as spi-
ronolactone, eplerenone, and amiloride, reported signifi-
cant antihypertensive benefits when added to a multiple 
drug regimen in patients with difficult-to-treat hyperten-
sion[19]. The antihypertensive effect of  spironolactone was 
evaluated in randomized trials and has proven efficacy, 
although results were more modest than initial expecta-
tions. Compared to a placebo, spironolactone 25 mg sig-
nificantly decreased mean daytime and nighttime ambula-
tory systolic BPs by 5.4 and 8.6 mmHg, respectively, with 
no significant change in diastolic pressure[20]. However, as 
suggested by the authors, it is possible that higher doses 
of  spironolactone could have had a greater impact on 
BP levels. Regarding which add-on therapy to use in re-
sistant hypertension, a recent study designed to compare 
spironolactone vs dual blockade of  the renin-angiotensin-
aldosterone system (RAS) has found that spironolactone 
has greater antihypertensive effect than dual blockade of  
the RAS in resistant hypertension[21].
Choice of  regimen: Regimens should be simplified 
and long-acting combination agents should be preferred, 
to improve efficacy and adherence to treatment. Non-
invasive hemodynamic studies assessing cardiac output, 
vascular resistance and intravascular volume may be 
considered to guide a pharmacological approach. While 
several studies have reported additive antihypertensive 
benefit by combining two different classes of  drugs, few 
studies have systematically evaluated the combination 
of  three or more medications in the treatment of  resis-
tant hypertension[2]. Considering no specific indication 
for a class of  drugs, a reasonable approach would be to 
sequentially combine agents with different mechanisms 
of  action to improve efficacy and drug tolerance. The 
use of  same-class combinations such as dihydropyri-
dine and non-dihydropyridine calcium channel block-
ers (CCB), combinations of  diuretic, an angiotensin-
converting enzyme inhibitor (ACEi) or an angiotensin 
receptor blocker (ARB) are not advocated over different 
classes of  antihypertensive agents. The latter combina-
tion therapy, with a recognizably larger biologic effect, 
was evaluated in The Ongoing Telmisartan Alone and 
in Combination with Ramipril Global Endpoint Trial[22], 
and despite the reported small reduction in systolic BP 
in the combination-therapy group as compared with the 
ramipril group, no significant benefit was seen among 
patients receiving the two-drug therapy. However, combi-
nation therapy adverse effects were significantly increased 
(hypotension, syncope, renal dysfunction and hyperkalae-
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mia). The authors concluded that no additional advan-
tage and possibly some harm could occur from this drug 
combination. Although the lack of  an additional benefit 
from a substantial lowering of  BP is puzzling, similar 
results were found in the VALIANT study[23], in which 
the combination of  a full dose of  captopril plus valsar-
tan did not significantly reduce the occurrence of  the 
primary outcome but there was an increase in treatment-
related adverse effects. Nonetheless, these findings con-
trast with a previous clinical trial done in a heart failure 
population, CHARM[24], in which candesartan added to 
existing therapy with any ACEi was superior to placebo 
in reducing deaths or hospitalization for heart failure.
Evidence-based recommendations in primary hy-
pertension consider an ACEi or ARB plus a CCB and 
a diuretic as the most rational triple drug treatment. 
Among patients who still have their BP uncontrolled 
with the triple drug regimen at maximum recommended 
and tolerable doses, spironolactone 25-50 mg/d should 
be added to the treatment. Further increases in spirono-
lactone doses are not recommended in the absence of  
documented primary aldosteronism. Adverse effects 
of  aldosterone antagonists are uncommonly seen with 
eplerenone use.
In primary hypertension, with no compelling indica-
tion for a beta-blocker (e.g., ischaemic heart disease or 
heart failure), patients should not receive a beta-blocker as 
the first-line of  treatment. Several studies have reported 
that beta-blockers are not as effective as other antihyper-
tensive drug classes in the prevention of  cardiovascular 
events of  uncomplicated hypertension, and the combina-
tion with thiazide diuretics increases the risk of  develop-
ing diabetes mellitus[1]. Nonetheless, beta-blockers are a 
reliable therapeutic option for uncontrolled hypertension 
and complicated hypertension, especially those with vaso-
dilating properties, such as carvedilol and nebivolol. Fur-
thermore, the association between beta and alpha-blockers 
may potentiate their antihypertensive effect[25].
The work by Hermida et al[26] in resistant hyperten-
sion underlined the importance of  ensuring at least one 
of  the antihypertensive drugs is taken at bedtime, in 
comparison with subjects receiving all drugs on awaken-
ing. This chronotherapeutic approach resulted in a sig-
nificant 60% increase in BP control, and a 32% improve-
ment in nighttime BP and in the prevalence of  a non-
dipper pattern, and should be implemented in resistant-
to-treatment patients.
Other available agents can be added sequentially 
in the presence of  persistent uncontrolled BP, such as 
centrally acting agents (clonidine, rilmenidine), or direct 
vasodilators (minoxidil, hydralazine). The two former 
pharmacological agents are potent vasodilators which 
should be reserved for cases of  hypertension refractory 
to the above-mentioned medications because of  fre-
quent adverse effects.
A work by Hanselin et al[27] retrospectively studied 
antihypertensive use in > 140 000 patients with resistant 
hypertension. With regard to antihypertensive class use, 
96.2% of  the resistant hypertension patients were on 
ACE inhibitors and/or ARBs, 93.2% were taking diuret-
ics, 83.6% a CCB, and 80.0% were on beta-blockers. Only 
3.0% of  patients were taking chlorthalidone and 5.9% 
aldosterone antagonists. Moreover, a total of  15.6% of  
patients were instead treated with ACE inhibitors plus 
ARB, which is not a first-line drug association. The au-
thors concluded that although guideline-recommended 
first-line agents were used frequently, effective medica-
tions such as chlorthalidone and aldosterone antagonists 
were still underused.
A recent study evaluated the patterns of  hypertension 
treatment, medication adherence, and treatment intensi-
fication (either increase in medication class or dose) in a 
resistant hypertension population[9]. The authors found 
that only 55% of  the patients achieved BP control one 
year after resistant hypertension identification. In the first 
year of  follow up the majority of  patients were adherent 
to their antihypertensive medications (median medication 
adherence rates were nearly 85%); however, the use of  
many antihypertensive medication classes declined over 
1 year, and one of  the largest drops was seen in diuretic 
use. The latter underlines the difficulty to maintain adher-
ence in patients with multiple antihypertensive regimens. 
One of  the most important findings of  this study was 
the evaluation of  the role of  therapy intensification in 
resistant hypertension patients. Over 1 year of  follow-
up, the intensification of  the treatment regimen occurred 
in only 21.6% of  visits with an elevated BP documented 
(10% had a class addition and 32% had a dose increase), 
which is much less than the expected intensification of  
the antihypertensive treatment for this high-risk group. 
However, the treatment intensification, but not treatment 
adherence, associated with improved BP control supports 
the importance of  therapy optimization in resistant hy-
pertension management.
Currently, BP remains uncontrolled in many cases 
despite the availability of  multiple antihypertensive drugs 
and the patient’s adherence to treatment. The absence 
of  novel antihypertensive drugs targeting new pathways 
has led to new treatment strategies using different com-
binations of  available drugs, particularly those targeting 
sodium balance and RAS, which are the major recogniz-
able factors affecting BP control. Some of  these new 
strategies combine different diuretic drugs that act on 
different nephron segments[28] and others combine dif-
ferent RAS blockers[29], both approaches theoretically 
minimise counter-regulatory mechanisms that often limit 
the antihypertensive effect of  the medical regimens. A 
recent work by Bobrie et al[30] compared the efficacy and 
safety of  two stepped-care strategies of  sequential neph-
ron blockage (SNB) vs sequential RAS blockage (SRASB) 
added to a triple standardized therapy regimen (including 
an ARB, CCB and thiazide) in patients with resistant hy-
pertension. The SNB strategy consisted of  the sequen-
tial addition of  low doses of  one to three other diuretics 
acting at different nephron segments (spironolactone, 
furosemide and amiloride), rather than the standard ap-
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proach of  increasing the dose of  a single diuretic or 
changing the class of  the diuretic. The rationale of  this 
novel approach is to minimise the effects of  intrarenal 
counterregulatory mechanisms that are triggered by the 
use of  diuretics acting at a single site. The SRASB strat-
egy consisted of  reinforcing RAS blockage by adding an 
ACEi and beta-blocker, in order to neutralise RAS coun-
terregulatory mechanisms. In this study, the SNB was 
more effective than SRASB. The incidence of  adverse 
events was similar in both groups and both treatment 
strategies were well tolerated. The authors concluded 
that progressive sodium depletion by the SNB strategy is 
effective to reduce BP in resistant hypertension patients. 
Moreover, antinatriuretic counterregulatory mechanisms 
seem to contribute more to uncontrolled hypertension 
pathophysiology than counterregulation inside the RAS. 
The choice of  other diuretic classes instead of  thiazide-
type drugs, such as chlorthalidone, or bumetanide in 
place of  furosemide, their doses and optimal sequence 
of  administration needs further study and definition.
Device-based therapies
Renal denervation: The role of  afferent and efferent 
sympathetic nerves in essential hypertension has been long 
recognised and recently reappraised. Efferent sympathetic 
outflow produces renal vasoconstriction, decreases renal 
blood flow, and increases renin release as well as sodium 
uptake, and afferent signals increase central sympathetic 
activity and contribute to neurogenic hypertension. A 
catheter-based radiofrequency ablation has been devel-
oped to selectively disrupt the renal nerves, and its ef-
ficacy and safety are supported by the Symplicity HTN-2 
trial[31] comprising resistant hypertension subjects who 
had a baseline systolic pressure ≥ 160 mmHg (≥ 150 
mmHg in diabetes type 2 patients). After 6 mo, office BP 
in the renal denervation group reduced by 32/12 mmHg 
from baseline, and home BP had a less pronounced 
reduction of  11/7 mmHg. The comparatively large 
discrepancy between the effects on clinic and ambula-
tory BP is noteworthy, and has been reported similarly 
by other study groups[32,33]. The antihypertensive effect 
seems to be sustained over 2 years. Moreover, the renal 
denervation registered a very favourable safety profile 
and was of  minor complexity. Although procedure ef-
fects on cardiovascular outcomes are not well estab-
lished, subsequent reports suggested important benefits 
in coexisting metabolic syndrome and sleep apnoea. 
Witkowski et al[32] concluded that renal denervation im-
proves indices of  insulin action and glucose metabolism 
(plasma glucose concentration 2 h after glucose admin-
istration: 7.0 mmol/L vs 6.4 mmol/L; hemoglobin A1C: 
6.1% vs 5.6%) as well as sleep apnea (apnea-hypopnea 
index: 16.3 events/h vs 4.5 events/h) at 6-mo follow up. 
A study by Brandt et al[34] has investigated the effect of  
catheter-based renal sympathetic denervation on left 
ventricular hypertrophy and systolic and diastolic func-
tion, parameters related to chronic activation of  the 
sympathetic nervous system and to increased mortality, 
in patients with resistant hypertension. This study found 
a significant reduction in left ventricular mass, left ven-
tricular filling pressures and left atrium dimensions, and 
a significant increase in ejection fraction. The prognostic 
importance of  these results is not yet clear, and it is not 
possible to distinguish what proportion of  these changes 
were caused by BP reduction or were related to the sym-
pathetic denervation per se. Nevertheless, the long-term 
improvement in left ventricular dimension and function 
may have significant morbidity and mortality impact, in 
addition to BP-lowering effect. Furthermore, the Sym-
plicity HF trial, designed to address the efficacy of  renal 
denervation in heart failure patients, will further define 
the usefulness of  this technique in other clinical settings 
besides resistant hypertension. 
Although catheter-based renal denervation opens new 
interesting therapeutic perspectives, there are several limi-
tations in the studies supporting this novel procedure that 
were recently reviewed by Steichen et al[35]. In the Sym-
plicity HTN-1 trial[36] there was no control group with 
which to make comparisons regarding BP and glomerular 
filtration rate responses over time. The number of  pa-
tients included in the pivotal studies[31,36] was small (205 
patients), and only a few have reached the 24-mo follow-
up time point. This limited follow-up appears not to be 
appropriate to exclude delayed adverse effects that may 
derive from the percutaneous technique. The study de-
sign was weak and may have exposed the investigators to 
several biases. It is of  note that secondary hypertension 
and white-coat hypertension were not properly excluded. 
The BP reductions should be carefully interpreted, as no 
intervention was proposed in the control group. It would 
be preferable to optimize the pharmacological approach 
in a standardized fashion in the two groups before ran-
domisation and to carry out a factitious intervention 
(sham) in the control group, to clearly establish the real 
added value of  the denervation procedure compared to 
the optimal medical therapy. In addition, office-based 
measurements of  BP were the main method used to 
evaluate procedure efficacy, which is not the preferable 
approach, particularly in an open study (placebo effect). 
The benefit for the BP control was much more modest 
in the ambulatory BP group than in the clinic reading 
group. Only a relatively small number of  the random-
ized patients had 24-h BP monitoring before and 6 mo 
after denervation, and the average reduction in systolic 
BP was only 11 mmHg, much less impressive than the 
32 mmHg reported in the office-based BP measure-
ments. The difference compared to the control group 
was only 8 mmHg, similar to the effect expected with 
the addition of  a new antihypertensive drug class. The 
experience from surgical renal denervation showed that 
the reduction in BP could be maintained over time[37]; 
however, long-term BP reduction after percutaneous 
renal denervation is uncertain. In the latter, denervation 
is less complete and sympathetic reinnervation may pos-
sibly be seen, a phenomenon well documented after renal 
transplantation. Moreover, the maintenance of  the BP 
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reduction was only reported in a small group of  patients 
followed over 24 mo (18 patients)[36]. A prolonged follow-
up of  these patients with noninvasive imaging would be 
essential to evaluate long-term possible lesions induced 
by the denervation ablation. Finally, there are no available 
results on morbidity or mortality. Despite the above con-
siderations, the European Society of  Cardiology Council 
for Cardiology Practice[38] considers catheter-based renal 
denervation useful, particularly in the treatment of  pa-
tients with hypertension coexisting with sleep apnea and 
metabolic syndrome. 
Carotid baroreflex activation: Another device-based 
therapy for resistant hypertension is carotid baroreflex ac-
tivation, consisting of  an implanted pulse generator and 
electrodes around carotid sinuses. The Rheos Baroreflex 
Hypertension Therapy System enhances afferent nerve 
outflow from the baroreceptors to the cardiovascular con-
trol centres of  the brain, reducing sympathetic outflow 
and, subsequently, BP. The Device-Based Therapy in Hy-
pertension Trial was a non-randomised study which doc-
umented carotid baroreflex activation effect on office and 
ambulatory BP of  patients with resistant hypertension[39]. 
The office BP reduced by an average of  21/12 mmHg 
and heart rate decreased by 8 beats/min from baseline, 
and the antihypertensive effect was sustained through 
the 24-mo follow up. However, in home BP monitoring 
the systolic BP was reduced nonsignificantly by 6 mmHg 
(P = 0.10), but with a significant decrease in diastolic 
BP (4 mmHg, P = 0.04), and in heart rate (5 beats/min, 
P < 0.001). Conversely, the subsequent randomised con-
trolled trial reported less convincing results, due to failure 
to meet endpoints for acute responders and procedural 
safety[40]. Moreover, the implantation’s complexity and 
invasiveness are a noteworthy limitation. Nonetheless, the 
development and investigation of  baroreflex activation 
therapy continues, and future clinical trials will further 
define its therapeutic benefit.
Table 1 summarizes the most relevant therapeutic 
approaches in resistant hypertension discussed in the 
manuscript.
CONCLUSION
Hypertension is one of  the most important prevent-
able causes of  premature morbidity and mortality, and 
despite the availability of  effective antihypertensive 
drugs, it remains uncontrolled in too many patients. The 
causes of  uncontrolled hypertension and the distinction 
between pseudoresistance and true resistant hyperten-
sion should be carefully pursued using a systematic ap-
proach to the patient. Understanding the pathophysiol-
ogy of  uncontrolled BP will help direct future efforts 
to improve the outcome in this high-risk population. 
The management of  resistant hypertension should be 
standardised and follow the current treatment guidelines, 
including device-based therapy in specific cases, which 
has shown encouraging results in BP, metabolic control, 
and heart dimensions and function. In the absence of  
novel antihypertensive drugs targeting new pathways, an 
active pursuit of  treatment intensification and the use 
of  different combinations of  antihypertensive drugs, 
particularly those targeting renal antinatriuretic counter-
regulatory mechanisms, may be an effective approach to 
manage truly resistant hypertension patients.
REFERENCES
1 Mansia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, 
Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent 
S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, 
Struijker Boudier HA, Zanchetti A. 2007 ESH-ESC Guide-
lines for the management of arterial hypertension: the task 
force for the management of arterial hypertension of the Eu-
ropean Society of Hypertension (ESH) and of the European 
281 September 26, 2012|Volume 4|Issue 9|WJC|www.wjgnet.com
  Usefulness Limitations
   Medical treatment
     Aldosterone antagonists High prevalence of primary aldosteronism
Higher efficacy than dual RAS blockade
70% of resistant-to-treatment hypertension cases are not con-
trolled with ≥ 4 antihypertensive drugs
Aldosterone antagonists cause frequent adverse effects, particu-
larly in kidney disease
     Sequential nephron/RAS blockade1 Act on sodium balance and RAS (major blood 
pressure determinants)
Sequential nephron blockade superior to RAS 
blockade
Sequential blockade benefits need further validation
Sequential nephron blockade regimen complexity
Potential higher incidence of adverse effects/poor tolerance
Needs regular medical evaluation
  Device–based therapy
     Catheter-based renal denervation Novel therapeutic target for resistant to drug 
treatment patients
Promising effects on glycemic control, sleep 
apnea and heart structure/function
Potential benefits in heart failure patients
Needs further validation of study results
Needs complete evaluation of delayed procedure complications
Not available to all uncontrolled blood pressure patients
Procedure success variability related to operator/patient factors
     Carotid baroreflex activation Novel therapeutic target for resistant to drug 
treatment patients
Needs further validation of study results
Implantation's complexity and invasiveness
Table  1  Summary of therapeutic approaches in resistant hypertension
1Added to triple antihypertensive treatment (ARB, thiazide, CCB). ARB: Angiotensin receptor blocker; CCB: Calcium channel blockers; RAS: Renin-angio-
tensin-aldosterone system.
Paiva L et al . Overview of resistant hypertension
Society of Cardiology (ESC). Blood Press 2007; 16: 135-232 
2 Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto 
RD, White A, Cushman WC, White W, Sica D, Ferdinand 
K, Giles TD, Falkner B, Carey RM. Resistant hypertension: 
diagnosis, evaluation, and treatment: a scientific statement 
from the American Heart Association Professional Educa-
tion Committee of the Council for High Blood Pressure Re-
search. Circulation 2008; 117: e510-e526 
3 Persell SD. Prevalence of resistant hypertension in the 
United States, 2003-2008. Hypertension 2011; 57: 1076-1080 
4 Pisoni R, Ahmed MI, Calhoun DA. Characterization and 
treatment of resistant hypertension. Curr Cardiol Rep 2009; 
11: 407-413 
5 Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi 
FA, Margolis KL, O’Connor PJ, Selby JV, Ho PM. Incidence 
and prognosis of resistant hypertension in hypertensive pa-
tients. Circulation 2012; 125: 1635-1642 
6 de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz 
JJ, Armario P, Oliveras A, Ruilope LM. Clinical features of 
8295 patients with resistant hypertension classified on the 
basis of ambulatory blood pressure monitoring. Hyperten-
sion 2011; 57: 898-902 
7 Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. 
Adherence to prescribed antihypertensive drug treatments: 
longitudinal study of electronically compiled dosing histo-
ries. BMJ 2008; 336: 1114-1117 
8 Burnier M, Schneider MP, Chioléro A, Stubi CL, Brunner 
HR. Electronic compliance monitoring in resistant hyperten-
sion: the basis for rational therapeutic decisions. J Hypertens 
2001; 19: 335-341 
9 Daugherty SL, Powers JD, Magid DJ, Masoudi FA, Margo-
lis KL, O’Connor PJ, Schmittdiel JA, Ho PM. The association 
between medication adherence and treatment intensifica-
tion with blood pressure control in resistant hypertension. 
Hypertension 2012; 60: 303-309 
10 Brown MA, Buddle ML, Martin A. Is resistant hypertension 
really resistant? Am J Hypertens 2001; 14: 1263-1269 
11 Lloyd-Jones DM, Evans JC, Larson MG, O’Donnell CJ, 
Roccella EJ, Levy D. Differential control of systolic and dia-
stolic blood pressure : factors associated with lack of blood 
pressure control in the community. Hypertension 2000; 36: 
594-599 
12 Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield 
SS, Harding SM, Calhoun DA. Plasma aldosterone is related 
to severity of obstructive sleep apnea in subjects with resis-
tant hypertension. Chest 2007; 131: 453-459 
13 Barbé F, Mayoralas LR, Duran J, Masa JF, Maimó A, Mont-
serrat JM, Monasterio C, Bosch M, Ladaria A, Rubio M, 
Rubio R, Medinas M, Hernandez L, Vidal S, Douglas NJ, 
Agustí AG. Treatment with continuous positive airway 
pressure is not effective in patients with sleep apnea but no 
daytime sleepiness. a randomized, controlled trial. Ann In-
tern Med 2001; 134: 1015-1023 
14 Pepperell JC, Ramdassingh-Dow S, Crosthwaite N, Mullins 
R, Jenkinson C, Stradling JR, Davies RJ. Ambulatory blood 
pressure after therapeutic and subtherapeutic nasal continu-
ous positive airway pressure for obstructive sleep apnoea: a 
randomised parallel trial. Lancet 2002; 359: 204-210 
15 Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, 
Weissmann P. Hyperaldosteronism among black and white 
subjects with resistant hypertension. Hypertension 2002; 40: 
892-896 
16 Kupper N, Willemsen G, Riese H, Posthuma D, Boomsma 
DI, de Geus EJ. Heritability of daytime ambulatory blood 
pressure in an extended twin design. Hypertension 2005; 45: 
80-85 
17 McManus RJ, Caulfield M, Williams B. NICE hypertension 
guideline 2011: evidence based evolution. BMJ 2012; 344: 
e181 
18 Ernst ME, Carter BL, Goerdt CJ, Steffensmeier JJ, Phillips 
BB, Zimmerman MB, Bergus GR. Comparative antihyper-
tensive effects of hydrochlorothiazide and chlorthalidone 
on ambulatory and office blood pressure. Hypertension 2006; 
47: 352-358 
19 Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-
dose spironolactone in subjects with resistant hypertension. 
Am J Hypertens 2003; 16: 925-930 
20 Václavík J, Sedlák R, Plachy M, Navrátil K, Plásek J, Jar-
kovsky J, Václavík T, Husár R, Kociánová E, Táborsky M. 
Addition of spironolactone in patients with resistant arterial 
hypertension (ASPIRANT): a randomized, double-blind, 
placebo-controlled trial. Hypertension 2011; 57: 1069-1075 
21 Alvarez-Alvarez B, Abad-Cardiel M, Fernandez-Cruz A, 
Martell-Claros N. Management of resistant arterial hyper-
tension: role of spironolactone versus double blockade of 
the renin-angiotensin-aldosterone system. J Hypertens 2010; 
28: 2329-2335 
22 Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, 
Dagenais G, Sleight P, Anderson C. Telmisartan, ramipril, 
or both in patients at high risk for vascular events. N Engl J 
Med 2008; 358: 1547-1559 
23 Cohn JN, Tognoni G. A randomized trial of the angiotensin-
receptor blocker valsartan in chronic heart failure. N Engl J 
Med 2001; 345: 1667-1675 
24 McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held 
P, Michelson EL, Olofsson B, Yusuf S, Pfeffer MA. Effects 
of candesartan in patients with chronic heart failure and re-
duced left-ventricular systolic function taking angiotensin-
converting-enzyme inhibitors: the CHARM-Added trial. 
Lancet 2003; 362: 767-771 
25 Townsend RR, DiPette DJ, Goodman R, Blumfield D, Cro-
nin R, Gradman A, Katz LA, McCarthy EP, Sopko G. Com-
bined alpha/beta-blockade versus beta 1-selective blockade 
in essential hypertension in black and white patients. Clin 
Pharmacol Ther 1990; 48: 665-675 
26 Hermida RC, Ayala DE, Calvo C, López JE, Mojón A, Fon-
tao MJ, Soler R, Fernández JR. Effects of time of day of treat-
ment on ambulatory blood pressure pattern of patients with 
resistant hypertension. Hypertension 2005; 46: 1053-1059 
27 Hanselin MR, Saseen JJ, Allen RR, Marrs JC, Nair KV. De-
scription of antihypertensive use in patients with resistant 
hypertension prescribed four or more agents. Hypertension 
2011; 58: 1008-1013 
28 Knauf H, Mutschler E. Sequential nephron blockade breaks 
resistance to diuretics in edematous states. J Cardiovasc Phar-
macol 1997; 29: 367-372 
29 Azizi M, Ménard J. Combined blockade of the renin-angio-
tensin system with angiotensin-converting enzyme inhibi-
tors and angiotensin II type 1 receptor antagonists. Circula-
tion 2004; 109: 2492-2499 
30 Bobrie G, Frank M, Azizi M, Peyrard S, Boutouyrie P, Chat-
ellier G, Laurent S, Menard J, Plouin PF. Sequential neph-
ron blockade versus sequential renin-angiotensin system 
blockade in resistant hypertension: a prospective, random-
ized, open blinded endpoint study. J Hypertens 2012; 30: 
1656-1664 
31 Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder 
RE, Böhm M. Renal sympathetic denervation in patients 
with treatment-resistant hypertension (The Symplicity 
HTN-2 Trial): a randomised controlled trial. Lancet 2010; 
376: 1903-1909 
32 Witkowski A, Prejbisz A, Florczak E, Kądziela J, Śliwiński P, 
Bieleń P, Michałowska I, Kabat M, Warchoł E, Januszewicz 
M, Narkiewicz K, Somers VK, Sobotka PA, Januszewicz A. 
Effects of renal sympathetic denervation on blood pressure, 
sleep apnea course, and glycemic control in patients with 
resistant hypertension and sleep apnea. Hypertension 2011; 
58: 559-565 
33 Egan BM. Renal sympathetic denervation: a novel interven-
tion for resistant hypertension, insulin resistance, and sleep 
282 September 26, 2012|Volume 4|Issue 9|WJC|www.wjgnet.com
Paiva L et al . Overview of resistant hypertension
apnea. Hypertension 2011; 58: 542-543 
34 Brandt MC, Mahfoud F, Reda S, Schirmer SH, Erdmann 
E, Böhm M, Hoppe UC. Renal sympathetic denervation 
reduces left ventricular hypertrophy and improves cardiac 
function in patients with resistant hypertension. J Am Coll 
Cardiol 2012; 59: 901-909 
35 Steichen O, Sapoval M, Frank M, Bobrie G, Plouin PF, Azizi 
M. . Presse Med 2012; 41: 349-357 
36 Symplicity HTN-1 Investigators. Catheter-based renal sym-
pathetic denervation for resistant hypertension: durability 
of blood pressure reduction out to 24 months. Hypertension 
2011; 57: 911-917 
37 Page IH, Heuer GJ. A surgical treatment of essential hyper-
tension. J Clin Invest 1935; 14: 22-26 
38 Wojakowski W, Tendera M, Jadczyk T, Januszewicz A, Wit-
kowski A. Catheter-based renal denervation. E-journal of the 
ESC Council for Cardiology Practice 2012; 10: No. 22. Available 
from: URL: http://www.escardio.org/communities/coun-
cils/ccp/e-journal/volume10/Pages/catheter-based-renal-
denervation-tendera-m-wojakowksy-w.aspx
39 Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JJ, 
Mohaupt MG, Luft FC, Haller H, Menne J, Engeli S, Ceral J, 
Eckert S, Erglis A, Narkiewicz K, Philipp T, de Leeuw PW. 
Novel baroreflex activation therapy in resistant hyperten-
sion: results of a European multi-center feasibility study. J 
Am Coll Cardiol 2010; 56: 1254-1258 
40 Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon 
AA, Schafer J, de Leeuw PW, Sica DA. Baroreflex activation 
therapy lowers blood pressure in patients with resistant 
hypertension: results from the double-blind, randomized, 
placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011; 
58: 765-773 
S- Editor  Cheng JX    L- Editor  Logan S    E- Editor  Li JY
283 September 26, 2012|Volume 4|Issue 9|WJC|www.wjgnet.com
Paiva L et al . Overview of resistant hypertension
